Becton Dickinson and Co (BDX) Expected to Announce Quarterly Sales of $4.12 Billion

Brokerages forecast that Becton Dickinson and Co (NYSE:BDX) will announce $4.12 billion in sales for the current quarter, according to Zacks. Nine analysts have issued estimates for Becton Dickinson and’s earnings. The lowest sales estimate is $4.07 billion and the highest is $4.17 billion. Becton Dickinson and posted sales of $2.97 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 38.7%. The company is scheduled to report its next quarterly earnings report on Tuesday, May 1st.

On average, analysts expect that Becton Dickinson and will report full year sales of $4.12 billion for the current year, with estimates ranging from $15.75 billion to $15.90 billion. For the next year, analysts forecast that the business will report sales of $17.71 billion per share, with estimates ranging from $17.65 billion to $17.83 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that follow Becton Dickinson and.

How to Become a New Pot Stock Millionaire

Becton Dickinson and (NYSE:BDX) last released its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.07. The company had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The business’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business posted $2.33 EPS.

Several equities analysts recently issued reports on BDX shares. Argus raised their price objective on Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research note on Thursday, December 14th. They noted that the move was a valuation call. Deutsche Bank set a $260.00 price objective on Becton Dickinson and and gave the stock a “buy” rating in a research note on Friday, December 29th. Evercore ISI started coverage on Becton Dickinson and in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $245.00 price objective on the stock. Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price objective on the stock in a research note on Wednesday, January 3rd. Finally, KeyCorp started coverage on Becton Dickinson and in a research note on Friday, January 5th. They set an “overweight” rating and a $260.00 price objective on the stock. Six investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Becton Dickinson and currently has an average rating of “Buy” and a consensus price target of $238.00.

BDX stock opened at $210.60 on Friday. Becton Dickinson and has a one year low of $175.66 and a one year high of $248.39. The company has a market capitalization of $58,173.98, a P/E ratio of 160.76, a PEG ratio of 1.59 and a beta of 1.18. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.93 and a current ratio of 1.54.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be given a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 1.42%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio is presently 229.01%.

In other Becton Dickinson and news, Director Timothy M. Ring sold 269,661 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total value of $58,737,559.02. Following the sale, the director now directly owns 295,753 shares of the company’s stock, valued at $64,420,918.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Timothy M. Ring sold 176 shares of the stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $218.27, for a total value of $38,415.52. Following the completion of the sale, the director now directly owns 170,688 shares in the company, valued at $37,256,069.76. The disclosure for this sale can be found here. Insiders sold 281,108 shares of company stock worth $61,321,396 over the last ninety days. 1.00% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Legacy Advisors LLC increased its position in Becton Dickinson and by 7,000.0% in the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after buying an additional 490 shares during the period. Amica Retiree Medical Trust increased its position in Becton Dickinson and by 325.0% in the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock worth $109,000 after buying an additional 390 shares during the period. Almanack Investment Partners LLC. acquired a new stake in Becton Dickinson and in the fourth quarter worth $109,000. FTB Advisors Inc. increased its position in Becton Dickinson and by 114.2% in the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 290 shares during the period. Finally, Advisors Preferred LLC acquired a new position in shares of Becton Dickinson and during the fourth quarter valued at $126,000. 83.35% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Becton Dickinson and Co (BDX) Expected to Announce Quarterly Sales of $4.12 Billion” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3294523/becton-dickinson-and-co-bdx-expected-to-announce-quarterly-sales-of-4-12-billion.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Get a free copy of the Zacks research report on Becton Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Procter & Gamble  Stock Rating Reaffirmed by Barclays
Procter & Gamble Stock Rating Reaffirmed by Barclays
Vista Outdoor  Downgraded by Zacks Investment Research
Vista Outdoor Downgraded by Zacks Investment Research
ProQR Therapeutics  Downgraded by Zacks Investment Research
ProQR Therapeutics Downgraded by Zacks Investment Research
Fresenius SE & Co KGaA  Given a €82.00 Price Target by Nord/LB Analysts
Fresenius SE & Co KGaA Given a €82.00 Price Target by Nord/LB Analysts
Investment Analysts’ Updated EPS Estimates for April, 25th
Investment Analysts’ Updated EPS Estimates for April, 25th
Omnicell Technologies  to Release Quarterly Earnings on Wednesday
Omnicell Technologies to Release Quarterly Earnings on Wednesday


© 2006-2018 Ticker Report. Google+.